BYANNLI

This brand name is authorized in Croatia, Ireland, Poland, Romania.

Active ingredients

The drug BYANNLI contains one active pharmaceutical ingredient (API):

1	Paliperidone UNII R8P8USM8FR - PALIPERIDONE PALMITATE
	Paliperidone is a selective blocking agent of monoamine effects, whose pharmacological properties are different from that of traditional neuroleptics. Even though paliperidone is a strong D2-antagonist, which is believed to relieve the positive symptoms of schizophrenia, it causes less catalepsy and decreases motor functions to a lesser extent than traditional neuroleptics.
	Read more about Paliperidone

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
BYANNLI Prolonged-release suspension for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N05AX13	Paliperidone	N Nervous system → N05 Psycholeptics → N05A Antipsychotics → N05AX Other antipsychotics
Discover more medicines within N05AX13

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
PL	Rejestru Produktów Leczniczych	100439307, 100439313, 100439320, 100439336, 100439342, 100439359
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W68385001, W68386001